Adrenocorticotropic hormone analog use for podocytopathies

References

• MeyrierAYTreatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?Kidney Int200976548749119494796
   PubMed Web of Science ®Google Scholar
• D’AgatiVDFogoABBruijnJAJennetteJCPathologic classification of focal segmental glomerulosclerosis: a working proposalAm J Kidney Dis201543236838214750104
   PubMed Web of Science ®Google Scholar
• HoganJRadhakrishnanJThe treatment of minimal change disease in adultsJ Am Soc Nephrol201324570271123431071
   PubMed Web of Science ®Google Scholar
• BeckLBombackASChoiMJKDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritisAm J Kidney Dis201562340344123871408
   PubMed Web of Science ®Google Scholar
• IijimaKSakoMNozuKRituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trialLancet201438499501273128124965823
   PubMed Web of Science ®Google Scholar
• BruchfeldABenedekSHildermanMMedinCSnaedal-JonsdottirSKorkeilaMRituximab for minimal change disease in adults: long-term follow-upNephrol Dial Transplant201429485185624121763
   PubMed Web of Science ®Google Scholar
• CattranDCAppelGBHebertLAA randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study GroupKidney Int19995662220222610594798
   PubMed Web of Science ®Google Scholar
• BraunNSchmutzlerFLangeCPernaARemuzziGWillisNSImmunosuppressive treatment for focal segmental glomerulosclerosis in adultsCochrane Database Syst Rev20083CD00323318646090
   PubMed Web of Science ®Google Scholar
• CanettaPARadhakrishnanJImpact of the national institutes of health focal segmental glomerulosclerosis (NIH FSGS) clinical trial on the treatment of steroid-resistant FSGSNephrol Dial Transplant201328352753423248028
   PubMed Web of Science ®Google Scholar
• GulatiASinhaAJordanSCEfficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric reportClin J Am Soc Nephrol20105122207221220798255
   PubMed Web of Science ®Google Scholar
• RapoportMMcCroryWWBarberoGBarnettHLFormanCWEffect of corticotropin (ACTH) on children with the nephrotic syndromeJ Am Med Assoc1951147121101110614873631
   PubMed Web of Science ®Google Scholar
• BarnettHLEffect of ACTH in children with the nephrotic syndromePediatrics19529334114911303
   PubMed Web of Science ®Google Scholar
• BergANilsson-EhlePArnadottirMBeneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathyKidney Int19995641534154310504505
   PubMed Web of Science ®Google Scholar
• PonticelliCPasseriniPSalvadoriMA randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathyAm J Kidney Dis200647223324016431252
   PubMed Web of Science ®Google Scholar
• PicardiLVillaGGalliFACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathyClin Nephrol200462540340415571191
   PubMed Web of Science ®Google Scholar
• BergAArnadottirMACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnosesNephrol Dial Transplant20041951305130715102969
   PubMed Web of Science ®Google Scholar
• RauenTMichaelisAFloegeJMertensPRCase series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24Clin Nephrol200971663764219473632
   PubMed Web of Science ®Google Scholar
• LindskogAEbeforsKJohanssonMEMelanocortin 1 receptor agonists reduce proteinuriaJ Am Soc Nephrol20102181290129820507942
   PubMed Web of Science ®Google Scholar
• BombackASRadhakrishnanJTreatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH)Discov Med20111263919621878186
   PubMed Web of Science ®Google Scholar
• BombackASCanettaPABeckLHJrAyalonRRadhakrishnanJAppelGBTreatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trialAm J Nephrol2012361586722722778
   PubMed Web of Science ®Google Scholar
• HoganJBombackASMehtaKTreatment of idiopathic FSGS with adrenocorticotropic hormone gelClin J Am Soc Nephrol20138122072208124009220
   PubMed Web of Science ®Google Scholar
• TumlinJAGalphinCMRovinBHAdvanced diabetic nephropathy with nephrotic range proteinuria: a pilot study of the long-term efficacy of subcutaneous ACTH gel on proteinuria, progression of CKD, and urinary levels of VEGF and MCP-1J Diabetes Res2013201348986924159603
   PubMed Web of Science ®Google Scholar
• HladunewichMACattranDBeckLHA pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathyNephrol Dial Transplant20142981570157724714414
   PubMed Web of Science ®Google Scholar
• LorussoPBottaiAMangioneEInnocentiMCupistiAEgidiMFLow-dose synthetic adrenocorticotropic hormone-analog therapy for nephrotic patients: results from a single-center pilot studyInt J Nephrol Renovasc Dis2015871225709493
   PubMedGoogle Scholar
• GongRThe renaissance of corticotropin therapy in proteinuric nephropathiesNat Rev Nephrol20128212212822143333
   PubMed Web of Science ®Google Scholar
• GongRLeveraging melanocortin pathways to treat glomerular diseasesAdv Chronic Kidney Dis201421213415124602463
   PubMed Web of Science ®Google Scholar
• BergALNilsson-EhlePDirect effects of corticotropin on plasma lipoprotein metabolism in man – studies in vivo and in vitroMetabolism199443190978289680
   PubMed Web of Science ®Google Scholar
• BergANilsson-EhlePACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney diseaseKidney Int19965025385428840283
   PubMed Web of Science ®Google Scholar
• GiganteARosatoELiberatoriMACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritisJ Biol Regul Homeost Agents201226113513822475105
   PubMed Web of Science ®Google Scholar
• WatsonMJMembranous glomerulopathy and treatment with Acthar®: a case studyInt J Nephrol Renovasc Dis2013622923224174881
   PubMedGoogle Scholar
• AnwarSLarsonDSNaimiNA case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoringFront Med (Lausanne)201521325853133
   PubMedGoogle Scholar
• MadanARepository corticotropin injection in a patient presenting with focal segmental glomerulosclerosis, rheumatoid arthritis, and optic neuritis: a case reportInt J Gen Med2015811912425848316
   PubMed Web of Science ®Google Scholar
• GipsonDSTrachtmanHKaskelFJClinical trial of focal segmental glomerulosclerosis in children and young adultsKidney Int201180886887821734640
   PubMed Web of Science ®Google Scholar
• BergARafnssonATJohannssonMDallongevilleJArnadottirMThe effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteinsMetabolism20065581083108716839845
   PubMed Web of Science ®Google Scholar
• FilipponeEJImmunosuppressive treatment of idiopathic membranous nephropathy: the dilemma continuesClin Nephrol201379214315323211341
   PubMed Web of Science ®Google Scholar
• AndersenGNHägglundMNagaevaOQuantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood leucocytesScand J Immunol200561327928415787746
   PubMed Web of Science ®Google Scholar
• CooperARobinsonSJPickardCJacksonCLFriedmannPSHealyEα-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene statusJ Immunol200517574806481316177130
   PubMed Web of Science ®Google Scholar
• CataniaAGattiSColomboGLiptonJMTargeting melanocortin receptors as a novel strategy to control inflammationPharmacol Rev200456112915001661
   PubMed Web of Science ®Google Scholar
• SahaliDPawlakAGouvelloSLTranscriptional and post-transcriptional alterations of IκBα in active minimal-change nephrotic syndromeJ Am Soc Nephrol20011281648165811461937
   PubMed Web of Science ®Google Scholar
• GuariniSCainazzoMMGiulianiDAdrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathwayCardiovasc Res200463235736515249194
   PubMed Web of Science ®Google Scholar
• TraceyKJThe inflammatory reflexNature2002420691785385912490958
   PubMed Web of Science ®Google Scholar
• ChhajlaniVDistribution of cDNA for melanocortin receptor subtypes in human tissuesBiochem Mol Biol Int199638173808932521
   PubMedGoogle Scholar
• Lindskog JonssonAGranqvistAElvinJJohanssonMEHaraldssonBNystromJEffects of melanocortin 1 receptor agonists in experimental nephropathiesPLoS One201491e8781624498203
   PubMed Web of Science ®Google Scholar
• QiaoYBergAGeYLiuZGongRMelanocortin 1 receptor (MC1R) is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapyJ Am Soc Nephrol20152664A
   Google Scholar
• GongRDworkinLDACTH (Acthar gel) prevents proteinuria and renal injury in the remnant kidney. Evidence for direct podocyte protectionJ Am Soc Nephrol201021548A20299354
   PubMed Web of Science ®Google Scholar
• GarciaDLRennkeHGBrennerBMAndersonSChronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablationJ Clin Invest19878038678743040810
   PubMed Web of Science ®Google Scholar
• XingCSaleemMACowardRJNiLWitherdenIRMathiesonPWDirect effects of dexamethasone on human podocytesKidney Int20067061038104516837924
   PubMed Web of Science ®Google Scholar
• FaulCDonnellyMMerscher-GomezSThe actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine ANat Med200814993193818724379
   PubMed Web of Science ®Google Scholar
• FornoniASageshimaJWeiCRituximab targets podocytes in recurrent focal segmental glomerulosclerosisSci Transl Med201138585ra46
   PubMed Web of Science ®Google Scholar